ABACAVIR SULFATE
| Title | Journal |
|---|---|
| T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. | Chemical research in toxicology 20130520 |
| N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. | British journal of pharmacology 20121101 |
| A case of adverse drug reaction induced by dispensing error. | Journal of forensic and legal medicine 20121101 |
| Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. | Journal of pharmacy practice 20121001 |
| Trade deal to curb generic-drug use. | Nature 20120906 |
| Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity. | Genetic testing and molecular biomarkers 20120901 |
| Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. | British journal of clinical pharmacology 20120801 |
| Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. | AIDS (London, England) 20120717 |
| Avidity determines T-cell reactivity in abacavir hypersensitivity. | European journal of immunology 20120701 |
| Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. | Journal of acquired immune deficiency syndromes (1999) 20120701 |
| Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. | Nature 20120628 |
| Pharmacology: A false sense of non-self. | Nature 20120627 |
| Detection of abacavir hypersensitivity by ELISpot method. | Inflammation & allergy drug targets 20120601 |
| Tools for eradicating HIV in the brain: prodrug dimeric inhibitors of P-gp. | Therapeutic delivery 20120601 |
| Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. | Gastroenterology 20120501 |
| Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. | British journal of clinical pharmacology 20120401 |
| [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency]. | Enfermedades infecciosas y microbiologia clinica 20120401 |
| HLA alleles and drug hypersensitivity reactions. | International journal of immunogenetics 20120401 |
| Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. | HIV medicine 20120401 |
| Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. | Clinical pharmacology and therapeutics 20120401 |
| Enantioselective synthesis of the carbocyclic nucleoside (-)-abacavir. | Organic & biomolecular chemistry 20120307 |
| Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. | AIDS research and human retroviruses 20120301 |
| Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. | Journal of the American Chemical Society 20120215 |
| Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. | Clinical pharmacology and therapeutics 20120201 |
| Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta. | Human immunology 20120201 |
| [Coinfection with HIV and HCV: abacavir and ribavirine, why not?]. | Revista clinica espanola 20120101 |
| Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. | Annual review of pharmacology and toxicology 20120101 |
| Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. | AIDS patient care and STDs 20120101 |
| Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. | PloS one 20120101 |
| Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. | Antiviral therapy 20120101 |
| Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction. | Antiviral therapy 20120101 |
| Genetics and the potential for predictive tests in adverse drug reactions. | Chemical immunology and allergy 20120101 |
| Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women. | Journal of the International AIDS Society 20120101 |
| The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series. | Antiviral therapy 20120101 |
| Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. | Chemical research in toxicology 20111219 |
| Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension. | The Journal of infectious diseases 20111215 |
| Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. | AIDS (London, England) 20111128 |
| Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. | AIDS (London, England) 20111023 |
| Abacavir and myocardial infarctions: the benefit of doubt? | AIDS (London, England) 20111023 |
| Optimizing initial therapy for HIV infection. | The Journal of infectious diseases 20111015 |
| Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. | The Journal of infectious diseases 20111015 |
| Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. | The Journal of infectious diseases 20111015 |
| A new approach to safely type for HLA the HIV infected people eligible to abacavir therapy: saliva or buccal swab as reliable DNA sources. | Clinica chimica acta; international journal of clinical chemistry 20111009 |
| Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. | The Journal of antimicrobial chemotherapy 20111001 |
| Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. | AIDS patient care and STDs 20111001 |
| [Raltegravir in a special case: patient with HIV and Burkitt's lymphoma]. | Deutsche medizinische Wochenschrift (1946) 20111001 |
| A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL. | The Journal of infectious diseases 20110915 |
| Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? | British journal of clinical pharmacology 20110901 |
| Abacavir and lamivudine for the treatment of human immunodeficiency virus. | Expert opinion on pharmacotherapy 20110901 |
| [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis]. | Medecine et maladies infectieuses 20110901 |
| Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic. | Central European journal of public health 20110901 |
| Medication-based urolithiasis and atazanavir. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110809 |
| Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. | The Journal of antimicrobial chemotherapy 20110801 |
| Treatment of Asian flush with abacavir. | Medical hypotheses 20110801 |
| Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries. | Journal of acquired immune deficiency syndromes (1999) 20110801 |
| Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. | Clinics (Sao Paulo, Brazil) 20110801 |
| Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allele-specific PCR method for prediction of hypersensitivity reaction to Abacavir. | Clinica chimica acta; international journal of clinical chemistry 20110715 |
| Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701 |
| HIV and Cardiovascular Disease. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110701 |
| Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. | AIDS (London, England) 20110619 |
| Acetoxy Meldrum's acid: a versatile acyl anion equivalent in the Pd-catalyzed asymmetric allylic alkylation. | Organic letters 20110617 |
| Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. | The Pediatric infectious disease journal 20110601 |
| Can fomepizole be substituted by abacavir in the treatment of methanol poisoning? | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20110601 |
| Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos. | Pharmacogenomics 20110601 |
| Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. | AIDS research and human retroviruses 20110501 |
| Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor. | Journal of fluorescence 20110501 |
| From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. | Expert opinion on drug safety 20110501 |
| Hypersensitivity reactions to HIV therapy. | British journal of clinical pharmacology 20110501 |
| FDA notifications. Abacavir sulfate tablets tentatively approved. | AIDS alert 20110501 |
| FDA notifications. Ongoing safety review of abacavir, possible MI risk. | AIDS alert 20110501 |
| No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110401 |
| Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. | Pharmacogenomics 20110401 |
| Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. | AIDS research and human retroviruses 20110201 |
| Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. | Tropical medicine & international health : TM & IH 20110201 |
| Recent FDA approvals and changes. | AIDS patient care and STDs 20110201 |
| Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS. | Journal of pharmaceutical and biomedical analysis 20110125 |
| The toxicogenetics of antiretroviral therapy: the evil inside. | Current medicinal chemistry 20110101 |
| Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions. | Journal of biopharmaceutical statistics 20110101 |
| Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. | BMC infectious diseases 20110101 |
| Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. | Internal medicine (Tokyo, Japan) 20110101 |
| [Efficacy and safety of the substitution of zidovudine by nevirapine in treatments based on three nucleoside analogue reverse transcriptase inhibitors in HIV-1 infected patients]. | Enfermedades infecciosas y microbiologia clinica 20110101 |
| Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. | PloS one 20110101 |
| Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. | Antiviral therapy 20110101 |
| Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system. | Antiviral therapy 20110101 |
| Increased prevalence of albuminuria in HIV-infected adults with diabetes. | PloS one 20110101 |
| Noninvasive coronary imaging for atherosclerosis in human immunodeficiency virus infection. | Current problems in diagnostic radiology 20110101 |
| Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy. | BMC infectious diseases 20110101 |
| Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. | Antiviral therapy 20110101 |
| The impact of pharmacogenetics in the treatment of allergic disease and asthma. | Missouri medicine 20110101 |
| Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. | Antiviral therapy 20110101 |
| Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. | Dermatologic therapy 20110101 |
| [HLA-B*5701 and abacavir hypersensitivity reaction]. | Pathologie-biologie 20101201 |
| HLA-B*5701 genetic screening prior to abacavir prescription in Georgia. | Georgian medical news 20101201 |
| Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. | AIDS (London, England) 20101113 |
| Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. | Enfermedades infecciosas y microbiologia clinica 20101101 |
| Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. | The Journal of antimicrobial chemotherapy 20101101 |
| FDA notifications. FDA approves generic abacavir. | AIDS alert 20101101 |
| Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101001 |
| The impact of gender and anchor drugs on TDF renal toxicity. | Journal of acquired immune deficiency syndromes (1999) 20101001 |
| Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. | Pharmacotherapy 20101001 |
| A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01. | Electrophoresis 20101001 |
| Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk. | AIDS (London, England) 20100924 |
| Use of abacavir in 30 HIV-infected children from Durban, South Africa: report from a pilot study. | The Pediatric infectious disease journal 20100901 |
| Development and validation of a selective and rapid LC-MS-MS method for the quantification of abacavir in human plasma. | Journal of chromatographic science 20100901 |
| Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. | AIDS (London, England) 20100824 |
| First report of abacavir associated with hypoglycemia. | AIDS (London, England) 20100824 |
| Abacavir and cardiovascular risk: reviewing the evidence. | Current HIV/AIDS reports 20100801 |
| Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. | The Journal of antimicrobial chemotherapy 20100801 |
| [Pharmacogenetics]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20100801 |
| Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. | Archives of internal medicine 20100726 |
| Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. | AIDS (London, England) 20100717 |
| Pharmacogenetics of drug hypersensitivity. | Pharmacogenomics 20100701 |
| Absence of mitochondrial toxicity in hearts of transgenic mice treated with abacavir. | Cardiovascular toxicology 20100601 |
| Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation. | AIDS (London, England) 20100601 |
| Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. | AIDS patient care and STDs 20100601 |
| Recent FDA approvals and changes. | AIDS patient care and STDs 20100601 |
| Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative. | AIDS (London, England) 20100515 |
| Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. | Medical mycology 20100501 |
| Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. | HIV medicine 20100501 |
| Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. | HIV medicine 20100501 |
| [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus]. | MMW Fortschritte der Medizin 20100429 |
| Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. | Pharmacogenomics 20100401 |
| Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. | AIDS (London, England) 20100327 |
| Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. | AIDS (London, England) 20100313 |
| Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects. | HIV medicine 20100301 |
| Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. | HIV medicine 20100301 |
| A model-based approach to dose selection in early pediatric development. | Clinical pharmacology and therapeutics 20100301 |
| [Durability and tolerability of long-term nevirapine-based HAART]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20100301 |
| Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. | HIV medicine 20100201 |
| Abacavir and cardiovascular risk. | Current opinion in infectious diseases 20100201 |
| HIV treatment information. | Project Inform perspective 20100201 |
| Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction. | AIDS (London, England) 20100128 |
| Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. | Archives of internal medicine 20100111 |
| Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. | Lancet (London, England) 20100109 |
| Pharmacogenetics of antiretrovirals. | Antiviral research 20100101 |
| Successful implementation of a national HLA-B*5701 genetic testing service in Canada. | Tissue antigens 20100101 |
| Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. | The Journal of infectious diseases 20100101 |
| Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. | Antiviral therapy 20100101 |
| The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. | Antiviral therapy 20100101 |
| Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. | Antiviral therapy 20100101 |
| Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. | HIV clinical trials 20100101 |
| Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. | European journal of medical research 20100101 |
| Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. | PharmacoEconomics 20100101 |
| Abacavir and CVD--more data but no consensus. Studies this year were evenly split, leaving patients and clinicians with few answers. | Journal watch. AIDS clinical care 20100101 |
| Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. | HIV clinical trials 20100101 |
| Anti-retroviral therapy-induced status epilepticus in 'pseudo-HIV serodeconversion'. | General hospital psychiatry 20100101 |
| Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. | Antiviral therapy 20100101 |
| The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. | PloS one 20100101 |
| HLA-B*5701 frequency in Chilean HIV-infected patients and in general population. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20100101 |
| A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. | HIV clinical trials 20100101 |
| Two-dimensional LC-MS/MS determination of antiretroviral drugs in rat serum and urine. | Journal of pharmaceutical and biomedical analysis 20091205 |
| Antiretroviral-induced toxic epidermal necrolysis in a patient positive for human immunodeficiency virus. | Clinical and experimental dermatology 20091201 |
| Abacavir and lamivudine combination. | Expert opinion on drug metabolism & toxicology 20091201 |
| Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. | AIDS research and human retroviruses 20091201 |
| Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. | Journal of pharmaceutical sciences 20091101 |
| A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. | AIDS patient care and STDs 20091101 |
| Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy. | HIV medicine 20091101 |
| Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study. | Infection 20091001 |
| Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again. | Journal watch. AIDS clinical care 20091001 |
| Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. | AIDS (London, England) 20090924 |
| B-mode ultrasound study of carotid plaques in HIV-positive patients to detect the presence of inflammatory endothelial lesions. | Current HIV research 20090901 |
| Virological response to initial antiretroviral regimens containing abacavir or tenofovir. | The Journal of infectious diseases 20090901 |
| Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. | Arteriosclerosis, thrombosis, and vascular biology 20090901 |
| [Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20090901 |
| FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets. | AIDS alert 20090901 |
| Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. | AIDS (London, England) 20090731 |
| The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells. | International journal of cancer 20090701 |
| A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. | Journal of acquired immune deficiency syndromes (1999) 20090701 |
| Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. | HIV medicine 20090701 |
| The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. | Journal of acquired immune deficiency syndromes (1999) 20090701 |
| Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). | AIDS research and human retroviruses 20090701 |
| Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir. | Transactions of the Royal Society of Tropical Medicine and Hygiene 20090601 |
| HLA and drug-induced toxicity. | Current opinion in molecular therapeutics 20090601 |
| Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. | Journal of acquired immune deficiency syndromes (1999) 20090501 |
| Abacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents. | Journal of acquired immune deficiency syndromes (1999) 20090501 |
| Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. | The Journal of antimicrobial chemotherapy 20090501 |
| Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only? | Current HIV research 20090501 |
| [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance]. | MMW Fortschritte der Medizin 20090430 |
| Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. | Journal of acquired immune deficiency syndromes (1999) 20090415 |
| Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection. | Journal of chromatography. A 20090410 |
| Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. | Clinical pharmacology and therapeutics 20090401 |
| Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. | The Journal of pharmacology and experimental therapeutics 20090401 |
| Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative. | International journal of STD & AIDS 20090401 |
| Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. | AIDS research and human retroviruses 20090401 |
| CROI 2009: a few key presentations on antiretroviral therapy. | The AIDS reader 20090401 |
| Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. | The AIDS reader 20090401 |
| Report from the 16th Conference on Retroviruses and Opportunistic Infections. Continued concern about abacavir and cardiovascular risk. | Journal watch. AIDS clinical care 20090401 |
| Aid agencies condemn drug confiscation. | BMJ (Clinical research ed.) 20090311 |
| Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus. | Archives of ophthalmology (Chicago, Ill. : 1960) 20090301 |
| Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. | The pharmacogenomics journal 20090201 |
| Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090201 |
| Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. | Pharmacogenomics 20090201 |
| FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine. | AIDS alert 20090201 |
| FDA notifications. Abacavir approved for pediatric patients. | AIDS alert 20090201 |
| [Atazanavir-induced nephrolithiasis]. | Enfermedades infecciosas y microbiologia clinica 20090201 |
| The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101 |
| Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. | The Journal of infectious diseases 20090101 |
| Top stories of 2008. Abacavir turmoil. | AIDS clinical care 20090101 |
| Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens. | AIDS clinical care 20090101 |
| Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? | Antiviral therapy 20090101 |
| Successful translation of pharmacogenetics into the clinic: the abacavir example. | Molecular diagnosis & therapy 20090101 |
| Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). | HIV clinical trials 20090101 |
| Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF. | HIV clinical trials 20090101 |
| HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. | Critical reviews in clinical laboratory sciences 20090101 |
| [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. | The pharmacogenomics journal 20081201 |
| Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. | The Journal of antimicrobial chemotherapy 20081201 |
| Abacavir and cardiovascular risk in HIV-infected patients: does T lymphocyte hyperactivation exert a pathogenic role? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081201 |
| Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. | Genetics in medicine : official journal of the American College of Medical Genetics 20081201 |
| Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC. | AIDS clinical care 20081201 |
| Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy. | AIDS (London, England) 20081130 |
| Abacavir-induced hepatotoxicity: a report of two cases. | AIDS (London, England) 20081130 |
| Generic lamivudine and abacavir approved. | AIDS patient care and STDs 20081101 |
| FDA notifications. Abacavir tablet approved for pediatric patients. | AIDS alert 20081101 |
| Abacavir-induced febrile agranulocytosis and anaemia. | AIDS (London, England) 20081018 |
| Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. | HIV medicine 20081001 |
| Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions. | AIDS patient care and STDs 20081001 |
| Comment: Abacavir hypersensitivity reaction: an update. | The Annals of pharmacotherapy 20081001 |
| The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. | AIDS (London, England) 20081001 |
| Current trends in screening across ethnicities for hypersensitivity to abacavir. | Pharmacogenomics 20081001 |
| FDA notifications. Generic abacavir and lamivudine combo approved. | AIDS alert 20081001 |
| The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. | The Journal of infectious diseases 20080915 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. | AIDS (London, England) 20080912 |
| The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. | American journal of human genetics 20080912 |
| Abacavir and increased risk of myocardial infarction. | Lancet (London, England) 20080906 |
| Abacavir and increased risk of myocardial infarction. | Lancet (London, England) 20080906 |
| Abacavir and increased risk of myocardial infarction. | Lancet (London, England) 20080906 |
| Cariogenic and erosive potential of the medication used by HIV-infected children: pH and sugar concentration. | Community dental health 20080901 |
| FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed. | AIDS alert 20080901 |
| Abacavir controversy continues to brew. | Project Inform perspective 20080901 |
| First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. | AIDS (London, England) 20080820 |
| Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. | HIV medicine 20080801 |
| The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. | Journal of acquired immune deficiency syndromes (1999) 20080801 |
| Labeling changes for abacavir. | AIDS patient care and STDs 20080801 |
| CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load. | The AIDS reader 20080801 |
| An unusual abacavir reaction. | AIDS (London, England) 20080731 |
| Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. | AIDS (London, England) 20080731 |
| Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients. | The Journal of infection 20080701 |
| Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study. | AIDS research and human retroviruses 20080701 |
| Abacavir hypersensitivity. | The New England journal of medicine 20080605 |
| Abacavir hypersensitivity. | The New England journal of medicine 20080605 |
| Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. | Immunity 20080601 |
| Pharmacogenomics of antiretrovirals. | Recent patents on anti-infective drug discovery 20080601 |
| A review of drug patch testing and implications for HIV clinicians. | AIDS (London, England) 20080531 |
| Abacavir and warfarin modulate allosterically kinetics of NO dissociation from ferrous nitrosylated human serum heme-albumin. | Biochemical and biophysical research communications 20080502 |
| Cardiac tamponade: an unusual complication of simultaneous treatment of tuberculosis and HIV. | Southern medical journal 20080501 |
| Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. | Journal of acquired immune deficiency syndromes (1999) 20080501 |
| FDA reviewing safety of Ziagen and Videx. | The AIDS reader 20080501 |
| [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided]. | Lakartidningen 20080501 |
| FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine. | AIDS alert 20080501 |
| [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance]. | Enfermedades infecciosas y microbiologia clinica 20080501 |
| [Prospective validation of a pharmacogenetic test: the PREDICT-1 study]. | Enfermedades infecciosas y microbiologia clinica 20080501 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. | Lancet (London, England) 20080426 |
| Abacavir and the potential risk of myocardial infarction. | Lancet (London, England) 20080426 |
| Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. | AIDS patient care and STDs 20080401 |
| Heart attack risk with abacavir and didanosine. | AIDS patient care and STDs 20080401 |
| High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080401 |
| Report from the 15th Retrovirus Conference. Is abacavir therapy associated with MI risk? | AIDS clinical care 20080401 |
| Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202. | AIDS clinical care 20080401 |
| Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301 |
| Abacavir hypersensitivity reaction: an update. | The Annals of pharmacotherapy 20080301 |
| Abacavir and didanosine increase the risk of heart attack. | AIDS patient care and STDs 20080301 |
| Anti-HIV agents. Controversial findings on abacavir and heart attacks. | TreatmentUpdate 20080301 |
| HLA-B*5701 screening for hypersensitivity to abacavir. | The New England journal of medicine 20080207 |
| Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. | The New England journal of medicine 20080207 |
| Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. | HIV medicine 20080201 |
| Pharmacogenetic information derived from analysis of HLA alleles. | Pharmacogenomics 20080201 |
| PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. | Pharmaceutical statistics 20080101 |
| Electrochemical determination of HIV drug Abacavir based on its reduction. | Analytical chemistry 20080101 |
| Treatment options for lipodystrophy in HIV-positive patients. | Expert opinion on pharmacotherapy 20080101 |
| Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. | HIV medicine 20080101 |
| Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. | HIV clinical trials 20080101 |
| Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). | Tropical medicine & international health : TM & IH 20080101 |
| New formulations approved for children. | AIDS patient care and STDs 20080101 |
| A review of the pharmacokinetics of abacavir. | Clinical pharmacokinetics 20080101 |
| Cytokine profiling in abacavir hypersensitivity patients. | Antiviral therapy 20080101 |
| Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study. | HIV clinical trials 20080101 |
| Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. | Antiviral therapy 20080101 |
| Incidence of abacavir hypersensitivity reactions in euroSIDA. | Antiviral therapy 20080101 |
| Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. | Antiviral therapy 20080101 |
| XVII International AIDS Conference--Mexico City, August 3-8, 2008. Can Ziagen hurt your heart? Research presented at the International AIDS Conference weighs in on the controversy. | Positively aware : the monthly journal of the Test Positive Aware Network 20080101 |
| Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. | Antiviral therapy 20080101 |
| Dosage adjustments in hepatic dysfunction. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20071215 |
| Screening for abacavir hypersensitivity. | AIDS alert 20071201 |
| Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. | AIDS (London, England) 20071130 |
| P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. | Drug metabolism and disposition: the biological fate of chemicals 20071101 |
| Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071101 |
| Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. | AIDS research and human retroviruses 20071101 |
| Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. | AIDS (London, England) 20071018 |
| Large lymphadenopathies complicating the abacavir hypersensitivity reaction. | AIDS (London, England) 20071018 |
| [Incidence and reasons of premature discontinuation of abacavir: results of a hospital investigation among 628 patients]. | Medecine et maladies infectieuses 20071001 |
| Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction. | AIDS (London, England) 20071001 |
| HLA-B*5701 clinical testing: early experience in the United States. | Pharmacogenetics and genomics 20071001 |
| Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Advances in HIV therapeutics: news from the 4th International AIDS Society Conference. | The AIDS reader 20071001 |
| Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity. | AIDS clinical care 20071001 |
| Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. | AIDS (London, England) 20070912 |
| A comparison of three initial antiretroviral AIDS regimens. | The New England journal of medicine 20070906 |
| Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. | Antiviral research 20070901 |
| Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. | The Journal of antimicrobial chemotherapy 20070901 |
| Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? | AIDS (London, England) 20070820 |
| Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase. | Journal of acquired immune deficiency syndromes (1999) 20070815 |
| Human leukocyte antigens and drug hypersensitivity. | Current opinion in allergy and clinical immunology 20070801 |
| Drug hypersensitivity in HIV. | Current opinion in allergy and clinical immunology 20070801 |
| Hair loss induced by lopinavir-ritonavir. | Pharmacotherapy 20070801 |
| Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. | Drug metabolism and disposition: the biological fate of chemicals 20070701 |
| HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. | Tissue antigens 20070701 |
| Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. | AIDS (London, England) 20070619 |
| Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK. | Sexually transmitted infections 20070601 |
| A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601 |
| 'Personalized medicine: elusive dream or imminent reality?': A commentary. | Clinical pharmacology and therapeutics 20070601 |
| Abacavir sulfate and mania in HIV. | The American journal of psychiatry 20070601 |
| HPV oral infection. Case report of an HIV-positive Nigerian sex worker. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20070601 |
| FDA notifications. FDA grants approval for generic didanosine for oral solution. | AIDS alert 20070601 |
| Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1. | AIDS (London, England) 20070511 |
| Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. | AIDS (London, England) 20070511 |
| Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Advances in HIV therapeutics: the 14th CROI. | The AIDS reader 20070501 |
| Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). | Journal of acquired immune deficiency syndromes (1999) 20070415 |
| Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. | The Journal of infectious diseases 20070415 |
| HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. | The Journal of antimicrobial chemotherapy 20070401 |
| Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. | AIDS patient care and STDs 20070401 |
| Identification of abacavir hypersensitivity reaction in health care claims data. | Pharmacoepidemiology and drug safety 20070301 |
| Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. | Pediatrics 20070301 |
| Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection. | Expert opinion on pharmacotherapy 20070301 |
| Abacavir modulates peroxynitrite-mediated oxidation of ferrous nitrosylated human serum heme-albumin. | Biochemical and biophysical research communications 20070209 |
| Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. | Journal of acquired immune deficiency syndromes (1999) 20070201 |
| Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. | AIDS (London, England) 20070130 |
| Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070101 |
| Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. | AIDS patient care and STDs 20070101 |
| Development and validation of a reverse-phase liquid chromatographic method for assay and related substances of abacavir sulfate. | Journal of separation science 20070101 |
| Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. | Environmental and molecular mutagenesis 20070101 |
| The NEFA study: results at three years. | AIDS reviews 20070101 |
| Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. | HIV clinical trials 20070101 |
| Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. | Antiviral therapy 20070101 |
| Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. | Antiviral therapy 20070101 |
| Complications and side effects. Abacavir hypersensitivity testing results--Montreal. | TreatmentUpdate 20070101 |
| External quality assessment of HLA-B*5701 reporting: an international multicentre survey. | Antiviral therapy 20070101 |
| Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20070101 |
| A new and short convergent synthetic strategy to carbocyclic nucleosides. | Nucleosides, nucleotides & nucleic acids 20070101 |
| [Pilot study of antiretroviral therapy in Djibouti]. | Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20070101 |
| In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. | Antimicrobial agents and chemotherapy 20061201 |
| Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy. | The Pediatric infectious disease journal 20061201 |
| Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review. | Medical science monitor : international medical journal of experimental and clinical research 20061201 |
| Abacavir/lamividune combination in the treatment of HIV-1 infection: a review. | Expert opinion on pharmacotherapy 20061201 |
| FDA approves generic abacavir sulfate tablets. | AIDS alert 20061201 |
| Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095. | AIDS clinical care 20061101 |
| A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. | AIDS (London, England) 20061024 |
| Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. | AIDS (London, England) 20061024 |
| The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line. | AIDS research and human retroviruses 20061001 |
| Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient. | Optometry (St. Louis, Mo.) 20060901 |
| Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine. | AIDS patient care and STDs 20060901 |
| Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. | JAMA 20060816 |
| The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. | Lancet (London, England) 20060805 |
| Human genetic variability and HIV treatment response. | Current HIV/AIDS reports 20060701 |
| A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. | The Journal of infectious diseases 20060701 |
| Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701 |
| Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701 |
| Synthesis of carbovir and abacavir from a carbocyclic precursor. | Current protocols in nucleic acid chemistry 20060701 |
| Investigating new antiretroviral combinations. | The Journal of infectious diseases 20060615 |
| Abacavir hypersensitivity reaction in primary HIV infection. | AIDS (London, England) 20060612 |
| Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060601 |
| Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. | The Pediatric infectious disease journal 20060601 |
| The clinical implications of antiretroviral pharmacogenomics. | Pharmacogenomics 20060601 |
| Bioequivalence of abacavir generic and innovator formulations under fasting and fed conditions. | International journal of clinical pharmacology and therapeutics 20060601 |
| [Antiretroviral treatment associated life-threatening adverse events]. | Medicina clinica 20060520 |
| A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. | Pharmacogenetics and genomics 20060501 |
| Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients? | International journal of clinical practice 20060501 |
| Abacavir prodrugs: microwave-assisted synthesis and their evaluation of anti-HIV activities. | Bioorganic & medicinal chemistry letters 20060415 |
| Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). | Journal of acquired immune deficiency syndromes (1999) 20060415 |
| Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient. | The Pediatric infectious disease journal 20060401 |
| Genetic factors in the predisposition to drug-induced hypersensitivity reactions. | The AAPS journal 20060301 |
| Impact of pregnancy on abacavir pharmacokinetics. | AIDS (London, England) 20060227 |
| Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. | Journal of acquired immune deficiency syndromes (1999) 20060201 |
| Acute respiratory manifestations of the abacavir hypersensitivity reaction. | AIDS (London, England) 20060109 |
| Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. | Pharmacogenomics 20060101 |
| An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. | Antiviral therapy 20060101 |
| Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. | Drug safety 20060101 |
| Genetic testing may avoid abacavir hypersensitivity reaction. | AIDS treatment news 20060101 |
| Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. | Journal of postgraduate medicine 20060101 |
| An immunological comparison of third companion in advanced drug-naive HIV-infected patients. | HIV clinical trials 20060101 |
| Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. | HIV clinical trials 20060101 |
| Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study. | HIV clinical trials 20060101 |
| [Development and validation of laboratory methods for antiretroviral quantitation using HPLC]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101 |
| Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen. | Antiviral therapy 20060101 |
| Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. | The Journal of infectious diseases 20051201 |
| Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. | The Journal of infectious diseases 20051201 |
| Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). | Journal of acquired immune deficiency syndromes (1999) 20051201 |
| Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. | Expert review of anti-infective therapy 20051201 |
| Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. | AIDS (London, England) 20051104 |
| Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. | HIV medicine 20051101 |
| Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. | AIDS (London, England) 20050902 |
| Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. | Journal of acquired immune deficiency syndromes (1999) 20050815 |
| Fatal lactic acidosis associated with tenofovir and abacavir. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20050701 |
| Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20050701 |
| Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. | Journal of acquired immune deficiency syndromes (1999) 20050701 |
| Abacavir dosing with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615 |
| Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. | AIDS (London, England) 20050610 |
| Clinical and immunogenetic correlates of abacavir hypersensitivity. | AIDS (London, England) 20050610 |
| [Consequences of replacing abacavir for indinavir in successful antiretroviral treatment of a patient with HIV infection]. | Presse medicale (Paris, France : 1983) 20050604 |
| Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. | Mutation research 20050603 |
| HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. | Tissue antigens 20050601 |
| A long-term survival case of small cell lung cancer in an HIV-infected patient. | Japanese journal of clinical oncology 20050601 |
| Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. | AIDS (London, England) 20050520 |
| Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. | Journal of medicinal chemistry 20050519 |
| Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. | The Journal of allergy and clinical immunology 20050501 |
| The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load. | HIV medicine 20050501 |
| Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients. | Journal of acquired immune deficiency syndromes (1999) 20050415 |
| Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. | Journal of acquired immune deficiency syndromes (1999) 20050401 |
| [Toxic epidermal necrolysis associated with abacavir]. | Enfermedades infecciosas y microbiologia clinica 20050401 |
| Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. | AIDS (London, England) 20050325 |
| Abacavir pharmacokinetics in hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050315 |
| Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. | Journal of clinical pharmacology 20050301 |
| Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050301 |
| Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients. | AIDS patient care and STDs 20050301 |
| Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study. | HIV medicine 20050301 |
| Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225 |
| A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). | The Journal of antimicrobial chemotherapy 20050201 |
| Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. | Journal of acquired immune deficiency syndromes (1999) 20050201 |
| Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients. | British journal of clinical pharmacology 20050201 |
| The impact of abacavir on lipids and lipodystrophy. | The AIDS reader 20050201 |
| GlaxoSmithKline receives European approval for Kivexa. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20050201 |
| Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. | AIDS (London, England) 20050103 |
| Lipoatrophy and mitochondrial DNA assays: see all, know all? | AIDS (London, England) 20050103 |
| Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101 |
| Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. | Drugs 20050101 |
| Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. | BMC infectious diseases 20050101 |
| Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. | AIDS patient care and STDs 20050101 |
| Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir. | AIDS clinical care 20050101 |
| Quadruple-drug induction HAART in advanced HIV infection. | HIV clinical trials 20050101 |
| Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. | BMC infectious diseases 20050101 |
| Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). | Antiviral therapy 20050101 |
| In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. | Antiviral therapy 20050101 |
| Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. | Clinical pharmacokinetics 20050101 |
| Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. | Antiviral therapy 20050101 |
| Once-daily abacavir in place of twice-daily administration. | The Annals of pharmacotherapy 20050101 |
| [An analisys fo causes for the discontinuation of a simplified antiretroviral regimen with abacavir, lamivudine and zidovudine]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050101 |
| Will pharmacogenomic discoveries improve HIV therapeutics? | Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101 |
| The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. | Current pharmaceutical design 20050101 |
| Failure of tenofovir + abacavir + 3TC combination; full report published, more insight. | AIDS treatment news 20050101 |
| Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. | HIV clinical trials 20050101 |
| Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. | HIV clinical trials 20050101 |
| Anti-HIV agents. Abacavir once or twice daily. | TreatmentUpdate 20050101 |
| Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? | Neurology 20041228 |
| More on abacavir-induced neuropsychiatric reactions. | AIDS (London, England) 20041203 |
| Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function. | Biomedical chromatography : BMC 20041201 |
| Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. | The Annals of pharmacotherapy 20041201 |
| Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study. | AIDS research and human retroviruses 20041201 |
| No rechallenge for abacavir. | AIDS patient care and STDs 20041201 |
| The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. | AIDS (London, England) 20041105 |
| Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. | AIDS (London, England) 20041105 |
| Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with (-)-carbovir. | Biochemical pharmacology 20041101 |
| [Risk factors for Abacavir-induced hypersensibility syndrome in the 'real world']. | Pathologie-biologie 20041101 |
| Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. | HIV medicine 20041101 |
| Tenofovir use in a patient with a severe renal impairment. | HIV medicine 20041101 |
| HLA-B*5701 and abacavir hypersensitivity. | Pharmacogenetics 20041101 |
| Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. | Journal of virological methods 20041001 |
| Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041001 |
| Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. | Antiviral therapy 20041001 |
| Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. | AIDS (London, England) 20040903 |
| Sweet's syndrome following abacavir therapy. | Journal of the American Academy of Dermatology 20040901 |
| Improved antiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) is due to the formation of markedly increased carbovir 5'-triphosphate metabolite levels. | FEBS letters 20040827 |
| Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. | AIDS (London, England) 20040820 |
| Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. | The Journal of infectious diseases 20040815 |
| Triple-nucleoside regimens versus efavirenz. | The New England journal of medicine 20040812 |
| Triple-nucleoside regimens versus efavirenz. | The New England journal of medicine 20040812 |
| Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. | Journal of acquired immune deficiency syndromes (1999) 20040801 |
| The pharmacogenetics of antiretroviral therapy: a review of studies to date. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040701 |
| Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. | The Journal of clinical endocrinology and metabolism 20040701 |
| Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). | Current medical research and opinion 20040701 |
| Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. | Current medical research and opinion 20040701 |
| In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease. | Antiviral research 20040601 |
| Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20040601 |
| Bringing genomics to the bedside: a cost-effective pharmacogenomic test? | Pharmacogenetics 20040601 |
| Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. | Pharmacogenetics 20040601 |
| Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. | AIDS (London, England) 20040430 |
| Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. | The New England journal of medicine 20040429 |
| [Valuable combination partner. Great benefit for therapy naive patients]. | MMW Fortschritte der Medizin 20040426 |
| Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. | AIDS (London, England) 20040409 |
| Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors. | Journal of neurovirology 20040401 |
| Abacavir hypersensitivity reaction predicted by genetic test. | AIDS treatment news 20040326 |
| Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. | Proceedings of the National Academy of Sciences of the United States of America 20040323 |
| [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges]. | Praxis 20040303 |
| Comment: Reasons for early abacavir discontinuation in HIV-infected patients. | The Annals of pharmacotherapy 20040301 |
| Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301 |
| Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. | Pharmacogenomics 20040301 |
| Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient. | AIDS (London, England) 20040220 |
| Managing HIV lipoatrophy. | Lancet (London, England) 20040207 |
| Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen. | Antiviral research 20040201 |
| Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20040201 |
| Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient. | AIDS (London, England) 20040123 |
| Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040115 |
| Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. | Antimicrobial agents and chemotherapy 20040101 |
| The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20040101 |
| Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. | Journal of acquired immune deficiency syndromes (1999) 20040101 |
| Determination of Abacavir in maternal plasma, amniotic fluid, fetal and placental tissues by a polarity switching liquid chromatography/tandem mass spectrometry method. | Rapid communications in mass spectrometry : RCM 20040101 |
| Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs? | Journal of neurovirology 20040101 |
| The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection. | Scandinavian journal of infectious diseases 20040101 |
| Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. | HIV clinical trials 20040101 |
| Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. | AIDS (London, England) 20040101 |
| EU issues warning about HAART regimen. | AIDS patient care and STDs 20040101 |
| Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients. | HIV clinical trials 20040101 |
| Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen. | The Annals of pharmacotherapy 20040101 |
| Pharmacogenetics to predict drug-related adverse events. | Toxicologic pathology 20040101 |
| K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens. | MedGenMed : Medscape general medicine 20040101 |
| Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). | Psychosomatics 20040101 |
| [Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20040101 |
| Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. | HIV clinical trials 20040101 |
| Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. | Lancet (London, England) 20031213 |
| TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. | AIDS (London, England) 20031205 |
| [Delayed drug sensitivity]. | Revista clinica espanola 20031201 |
| A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. | Antiviral therapy 20031201 |
| The continuing evolution of HIV therapy. | The AIDS reader 20031201 |
| Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. | AIDS (London, England) 20031121 |
| Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. | AIDS (London, England) 20031121 |
| Unusual clinical presentation of hypersensitivity reaction to abacavir. | AIDS (London, England) 20031107 |
| Triple combinations regimens for HIV. | The Lancet. Infectious diseases 20031101 |
| Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. | Pharmacotherapy 20031101 |
| Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone. | The AIDS reader 20031101 |
| Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abacavir as initial therapy and as a once-daily drug. | AIDS clinical care 20031101 |
| Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir. | AIDS clinical care 20031101 |
| Early nonresponse for tenofovir regimen. | AIDS patient care and STDs 20031101 |
| [Hypersensitive reaction to abacavir or syphilitic hepatitis?]. | Presse medicale (Paris, France : 1983) 20031011 |
| Reasons for early abacavir discontinuation in HIV-infected patients. | The Annals of pharmacotherapy 20031001 |
| Epidemiological risk factors for hypersensitivity reactions to abacavir. | HIV medicine 20031001 |
| Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20031001 |
| Warning issued on non-response rates. | AIDS patient care and STDs 20031001 |
| Anti-HIV agents. Trying times for tenofovir and abacavir. | TreatmentUpdate 20031001 |
| Anti-HIV agents. Abacavir--as good as AZT? | TreatmentUpdate 20031001 |
| Anti-HIV agents. Abacavir only once-daily. | TreatmentUpdate 20031001 |
| Anti-HIV agents. Who gets abacavir allergies? | TreatmentUpdate 20031001 |
| Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. | AIDS (London, England) 20030926 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. | The New England journal of medicine 20030911 |
| [Antiretroviral-induced toxiderma in HIV-infected patients]. | Presse medicale (Paris, France : 1983) 20030906 |
| Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901 |
| GlaxoSmithKline halts AIDS study. | The Lancet. Infectious diseases 20030901 |
| Perspectives on HAART: switch maintenance therapy. | International journal of STD & AIDS 20030901 |
| Capillary electrophoresis-ion trap mass spectrometry analysis of Ziagen and its phosphorylated metabolites. | Electrophoresis 20030901 |
| Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data. | AIDS clinical care 20030901 |
| Clinically relevant interpretation of genotype for resistance to abacavir. | AIDS (London, England) 20030815 |
| Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| [Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone]. | Revista clinica espanola 20030801 |
| Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. | The Journal of infectious diseases 20030801 |
| A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. | Antiviral therapy 20030801 |
| Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. | Antiviral therapy 20030801 |
| Early intensification with abacavir in subjects at high risk for incomplete viral suppression. | Antiviral therapy 20030801 |
| Failure of combination abacavir + tenofovir + lamivudine (3TC). | AIDS treatment news 20030725 |
| Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. | International journal of STD & AIDS 20030701 |
| AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial. | The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701 |
| Abandon Trizivir when it's working well? A rebuttal. | The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20030701 |
| Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. | Antimicrobial agents and chemotherapy 20030601 |
| Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601 |
| Cutaneous manifestations of antiviral therapy. | Journal of the American Academy of Dermatology 20030601 |
| A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. | Journal of acquired immune deficiency syndromes (1999) 20030501 |
| Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20030501 |
| Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? | Journal of HIV therapy 20030501 |
| Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. | Journal of HIV therapy 20030501 |
| Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. | AIDS (London, England) 20030411 |
| Abacavir arm stopped in clinical trial. | AIDS treatment news 20030404 |
| Antiretroviral therapy-induced psychosis: case report and brief review of the literature. | HIV medicine 20030401 |
| HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. | Antiviral therapy 20030401 |
| Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling. | Antiviral therapy 20030401 |
| Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. | Antiviral therapy 20030401 |
| K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. | Antiviral therapy 20030401 |
| Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a case report. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20030301 |
| Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection. | AIDS (London, England) 20030214 |
| Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. | Antiviral therapy 20030201 |
| Thymidine analogue-sparing highly active antiretroviral therapy (HAART). | Journal of HIV therapy 20030201 |
| Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. | The Journal of infectious diseases 20030101 |
| Lamivudine/zidovudine/abacavir: triple combination tablet. | Drugs 20030101 |
| Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. | HIV clinical trials 20030101 |
| Clinical vignette in antiretroviral therapy: rash illness. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20030101 |
| Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen. | Positively aware : the monthly journal of the Test Positive Aware Network 20030101 |
| Thrombotic thrombocytopenic purpura associated with abacavir in a patient with HIV infection. | Journal of intensive care medicine 20030101 |
| Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. | AIDS (London, England) 20021206 |
| Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). | Antiviral therapy 20021201 |
| Chronic cough induced by abacavir apart from a context of hypersensitivity. | Allergie et immunologie 20021201 |
| The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. | Chemico-biological interactions 20021110 |
| Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. | AIDS (London, England) 20021108 |
| The importance of being modest--reflections on the pharmacogenetics of abacavir. | Pharmacogenomics 20021101 |
| Neuropsychiatric reaction induced by abacavir. | The American journal of medicine 20021101 |
| Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. | The Journal of biological chemistry 20021025 |
| The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. | AIDS (London, England) 20021018 |
| Stevens-Johnson syndrome associated with abacavir therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021001 |
| Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. | Journal of acquired immune deficiency syndromes (1999) 20021001 |
| Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. | Journal of acquired immune deficiency syndromes (1999) 20021001 |
| The abacavir hypersensitivity reaction: a review. | Clinical therapeutics 20021001 |
| The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. | Journal of acquired immune deficiency syndromes (1999) 20020901 |
| Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction. | AIDS (London, England) 20020816 |
| FDA notifications. Product tampering labels Ziagen as Combivir. | AIDS alert 20020801 |
| Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. | JAMA 20020710 |
| Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. | JAMA 20020710 |
| Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. | AIDS (London, England) 20020705 |
| Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. | Antiviral research 20020701 |
| Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy. | The Journal of pediatrics 20020701 |
| Genome-based pharmacogenetics and the pharmaceutical industry. | Nature reviews. Drug discovery 20020701 |
| Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. | AIDS (London, England) 20020614 |
| Intracellular carbovir triphosphate levels in patients taking abacavir once a day. | AIDS (London, England) 20020524 |
| Therapeutic vaccination in primary HIV infection, the Quest trial. | Vaccine 20020506 |
| Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks. | AIDS (London, England) 20020503 |
| Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. | AIDS (London, England) 20020503 |
| A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. | The Journal of infectious diseases 20020501 |
| Abacavir hypersensitivity reaction. | AIDS patient care and STDs 20020501 |
| HLA B57 and abacavir hypersensitivity. | The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20020501 |
| Abacavir hypersensitivity reaction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415 |
| Scientists find some genes a bad omen for anti-HIV drug. | JAMA 20020403 |
| Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. | Antiviral research 20020401 |
| Risk factor analysis of hypersensitivity reactions to abacavir. | Clinical therapeutics 20020401 |
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. | Lancet (London, England) 20020330 |
| Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. | AIDS (London, England) 20020329 |
| Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. | AIDS (London, England) 20020308 |
| Individualising HIV treatment--pharmacogenetics and immunogenetics. | Lancet (London, England) 20020302 |
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. | Lancet (London, England) 20020302 |
| Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. | Lancet (London, England) 20020302 |
| Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. | Antiviral therapy 20020301 |
| Switching to abacavir to reduce fat wasting. | TreatmentUpdate 20020301 |
| Using abacavir to avoid lipid problems. | TreatmentUpdate 20020301 |
| Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215 |
| Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215 |
| HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. | AIDS (London, England) 20020215 |
| Efficacy of highly active antiretroviral therapy in HIV-1 infected children. | The Lancet. Infectious diseases 20020201 |
| Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. | AIDS research and human retroviruses 20020120 |
| Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. | Antiviral research 20020101 |
| Kawasaki-like syndrome: abacavir hypersensitivity? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020101 |
| Antiretroviral rounds. A very discordant response. | AIDS clinical care 20020101 |
| Vertigo and abacavir. | AIDS patient care and STDs 20020101 |
| Easier abacavir regimen has promising results. | AIDS alert 20020101 |
| 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections. | Positive living (Los Angeles, Calif.) 20020101 |
| Selected topics from the 9th Conference on Retroviruses and Opportunistic Infections. | HIV clinical trials 20020101 |
| Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. | AIDS (London, England) 20011207 |
| Agranulocytosis and fever seven weeks after starting abacavir. | AIDS (London, England) 20011207 |
| Understanding drug hypersensitivity: what to look for when prescribing abacavir. | The AIDS reader 20011201 |
| Editorial comment: the challenge of prescribing abacavir. | The AIDS reader 20011201 |
| Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. | Proceedings of the National Academy of Sciences of the United States of America 20011120 |
| Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. | AIDS (London, England) 20011109 |
| The role of NNRTIs in antiretroviral combination therapy: an introduction. | International journal of STD & AIDS 20011101 |
| Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. | European journal of medical research 20011029 |
| High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid. | Journal of chromatography. B, Biomedical sciences and applications 20011025 |
| Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015 |
| Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. | Therapeutic drug monitoring 20011001 |
| Hypersensitivity related to abacavir in two members of a family. | The Annals of pharmacotherapy 20011001 |
| Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. | Clinical therapeutics 20011001 |
| HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. | AIDS (London, England) 20010928 |
| Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. | The Journal of infectious diseases 20010915 |
| [Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination]. | MMW Fortschritte der Medizin 20010906 |
| Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. | The Journal of pharmacology and experimental therapeutics 20010901 |
| Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. | Nephron 20010901 |
| Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. | Antiviral chemistry & chemotherapy 20010901 |
| Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. | AIDS (London, England) 20010817 |
| The abacavir hypersensitivity reaction and interruptions in therapy. | AIDS (London, England) 20010706 |
| Resistance and cross-resistance to abacavir. | HIV medicine 20010701 |
| Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. | Antiviral therapy 20010601 |
| Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment. | Antiviral therapy 20010601 |
| A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. | Antiviral therapy 20010601 |
| Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010501 |
| Choosing which nuke to use first. | The AIDS reader 20010501 |
| Drifting agenda for federal treatment research. | GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20010501 |
| Resistant to everything. | AIDS clinical care 20010501 |
| Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Biomedical sciences and applications 20010425 |
| HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. | AIDS (London, England) 20010413 |
| [Observational study with abacavir. Decreased viral load and quality of life improves]. | MMW Fortschritte der Medizin 20010402 |
| [Determining resistance in HIV therapy. Careful interpretation only]. | MMW Fortschritte der Medizin 20010402 |
| An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | Controlled clinical trials 20010401 |
| A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. | Pharmacotherapy 20010401 |
| Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients. | Journal of acquired immune deficiency syndromes (1999) 20010401 |
| A near-fatal hypersensitivity reaction to abacavir: case report and literature review. | The AIDS reader 20010401 |
| Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. | JAMA 20010307 |
| Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection. | The Journal of infectious diseases 20010301 |
| International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. | Journal of acquired immune deficiency syndromes (1999) 20010301 |
| Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption. | Journal of clinical pharmacology 20010301 |
| Phase III trials for new PI. | AIDS patient care and STDs 20010301 |
| Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study. | The Journal of infectious diseases 20010215 |
| Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. | AIDS (London, England) 20010126 |
| Abacavir and diabetes. | The New England journal of medicine 20010111 |
| Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection. | Journal of chromatography. B, Biomedical sciences and applications 20010105 |
| A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. | Pediatrics 20010101 |
| Trizivir on the market. | Trends in microbiology 20010101 |
| Triple-drug tablet approved for HIV infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101 |
| Triple nuke therapy--results after one year. | TreatmentUpdate 20010101 |
| Abacavir sulfate, lamivudine, and zidovudine (Trizivir). | The Journal of the Association of Nurses in AIDS Care : JANAC 20010101 |
| Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial. | HIV medicine 20010101 |
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | AIDS research and human retroviruses 20000410 |
| Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. | Journal of acquired immune deficiency syndromes (1999) 19990815 |
| Four new antiretroviral medications will soon offer more options to HIV patients. | Faculty notes (New Orleans, La.) 19980101 |
| 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. | Antimicrobial agents and chemotherapy 19970501 |
| Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. | Antimicrobial agents and chemotherapy 19970501 |
| Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. | Antimicrobial agents and chemotherapy 19970501 |